Table 4.
Comparison of CHASER, R‐DHAP, R‐ESHAP and R‐ICE in relapsed or refractory aggressive B‐cell non‐Hodgkin's lymphoma (doses are per course)
| CHASER | R‐DHAP( 9 ) | R‐ESHAP( 7 ) | R‐ICE( 6 ) | |
|---|---|---|---|---|
| Rituximab | 375 mg/m2 × 1 | 375 mg/m2 × 1 | 375 mg/m2 weekly × 8 | 375 mg/m2 × 1 |
| Cytarabine | 2 g/m2 × 2 | 2 g/m2 × 2 | 2 g/m2 × 1 | – |
| Etoposide | 100 mg/m2 × 3 | – | 40 mg/m2 × 4 | 100 mg/m2 × 3 |
| Steroid | Dexamethasone 40 mg × 3 | Dexamethasone 40 mg × 4 | Methylprednisolone 500 mg × 5 | – |
| Platinum agent | – | Cisplatin 25 mg/m2 × 4 | Cisplatin 25 mg/m2 × 4 | Carboplatin AUC 5 × 1 |
| Non‐platinum alkylator | Cyclophosphamide 1200 mg/m2 × 1 | – | – | Ifosfamide 5 g/m2 × 1 |
| No. of patients | 15 | 53 | 26 | 36 |
| Prior rituximab exposure (%) | 53 | 4 | 19 † | 0 |
| CR rate % (95% CI) | 53 (27–79) | 32 (20–46) | 46 (27–65) | 53 (36–69) |
| OR rate % (95% CI) | 67 (38–88) | 62 (48–75) | 92 (82–100) | 78 (61–90) |
†
L. Hicks et al., 2007, personal communication; –, not included in treatment; AUC, area under the curve; CI, confidence interval; CR, complete response; OR, overall survival.